Loading...
Market
What will be the outcome of Eli Lilly's investment in the UK biotech sector by end of 2025?
2
Resolution / Starting Odds
Major success • 25%
Moderate success • 25%
Limited success • 25%
Failure • 25%
Financial reports from Eli Lilly or industry analysis reports
Story
Eli Lilly to Invest £279 Million ($364 Million) in UK Biotech and Weight-Loss Jabs Trial
Oct 15, 2024, 07:56 AM
Eli Lilly plans to invest £279 million ($364 million) in the UK to support biotechs and conduct research on the impact of its drugs for diabetes and obesity on healthcare resources. This investment is part of a broader initiative that includes a government-backed trial to provide weight-loss jabs to unemployed individuals with obesity. Health Secretary Wes Streeting announced the trial, which aims to help the unemployed return to work and reduce NHS costs. Prime Minister Keir Starmer has endorsed the initiative. The initiative has sparked debate on its potential economic benefits and ethical implications.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Yes • 50%
No • 50%
Approved for preventive use • 25%
Approved with restrictions • 25%
Rejected • 25%
No decision • 25%
Less than $25 billion • 25%
$25 billion to $30 billion • 25%
$30 billion to $35 billion • 25%
More than $35 billion • 25%
Below $900 • 25%
$900 to $950 • 25%
$950 to $1000 • 25%
Above $1000 • 25%
Yes • 50%
No • 50%
Less than $500 • 25%
$500 to $600 • 25%
$600 to $700 • 25%
More than $700 • 25%